SCHEMBL20722091

SCHEMBL20722091

NC12CC(c3nnc(-c4cncc(F)c4)o3)(C1)C2

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NQO2 P16083 1/20 0.33
▸ ADORA2B P29275 1/20 0.33
▸ ABL1 P00519 1/20 0.32
▸ RIN1 Q13671 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ CYP11B2 P19099 4/20 0.32
▸ CYP11B1 P15538 2/20 0.32
▸ CTSD P07339 1/20 0.32
▸ BACE1 P56817 1/20 0.32
▸ NPC1 O15118 2/20 0.31
▸ RAB9A P51151 2/20 0.31
▸ HTT P42858 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ TSHR P16473 1/20 0.30
▸ SMN1; SMN2 Q16637 1/20 0.30
▸ HSD17B10 Q99714 1/20 0.30
▸ POLB P06746 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL23359012 0.89 CYP11B2 (0.35) ABL1CYP11B2CYP11B1
Trifluoroacetic Acid SCHEMBL29435983 0.89 CYP11B2 (0.35) ABL1CYP11B2CYP11B1
SCHEMBL20722096 0.76 NOTUM (0.37) ALDH1A1BACE1NPC1RAB9ATP53
SCHEMBL30873658 0.74 ATF4 (0.36) CYP11B2CYP11B1BACE1
SCHEMBL23358982 0.74 ATF4 (0.36) CYP11B2CYP11B1BACE1
SCHEMBL24462414 0.74 KDM4E (0.51) ALDH1A1NPC1RAB9AHTTTP53
SCHEMBL30574771 0.67 HDAC6 (0.47) —
SCHEMBL2042399 0.65 CYP11B1 (0.42) ALDH1A1CYP11B2CYP11B1BACE1NPC1
SCHEMBL12419550 0.63 NPC1 (0.47) CYP11B2CYP11B1NPC1RAB9ATP53
SCHEMBL17952752 0.62 CYP11B2 (0.53) CYP11B2CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2023-12-26 — — US disclosed
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. 2022-12-29 — — US disclosed
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods DENALI THERAPEUTICS INC. (US) 2022-02-01 — — US disclosed
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. 2021-05-20 — — US disclosed
EP-3665156-A1 COMPOUNDS, COMPOSITIONS AND METHODS Denali Therapeutics Inc. (US) 2020-06-17 — — EP disclosed
WO-2019032743-A1 COMPOUNDS, COMPOSITIONS AND METHODS DENALI THERAPEUTICS INC. (US) 2019-02-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11236100-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 NQO2 1621/4885ADORA2B 1810/4885ABL1 2313/4885
US-11851440-B2 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 NQO2 1621/4885ADORA2B 1810/4885ABL1 2313/4885
US-20220411433-A1 Modulators of eukaryotic initiation factor 2B, compositions and methods EIF4EBP1, EIF4B, EIF2B2 NQO2 1621/4885ADORA2B 1810/4885ABL1 2313/4885
US-20210147435-A1 COMPOUNDS, COMPOSITIONS AND METHODS EIF4EBP1, EIF4B, EIF4E NQO2 1331/4885ADORA2B 723/4885ABL1 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback